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ABSTRACT: Ibuprofen and mefenamic acid are weak, com-
petitive inhibitors of cyclooxygenase-2 (COX-2) oxygena-
tion of arachidonic acid (AA) but potent, noncompetitive
inhibitors of 2-arachidonoylglycerol (2-AG) oxygenation.
Theslow,tight-bindinginhibitor,indomethacin,isapotent
inhibitorof2-AGandAAoxygenationwhereastherapidly
reversibleinhibitor,20-des-methylindomethacin,isapotent
inhibitor of 2-AG oxygenation but a poor inhibitor of AA
oxygenation. These observations are consistent with a
model in which inhibitors bind in one subunit of COX-2
and inhibit 2-AG binding inthe other subunitof thehomo-
dimeric protein. In contrast, ibuprofen and mefenamate
must bind in both subunits to inhibit AA binding.
Cyclooxygenase (COX)
1 enzymes oxygenate polyunsaturated
fatty acids to prostaglandin endoperoxides in the first step of
ametaboliccascadethatleadstothegenerationofprostaglandins
and thromboxanes. Inhibition of COX enzymes, especially COX-2,
is a major contributor to the pharmacological effects of non-
steroidal anti-inflammatory drugs (NSAIDs). COXs are homo-
dimers of 70 kDa subunits that are comprised of membrane-
bindingand catalyticdomains(1).Thecyclooxygenaseactivesite
is located deep inside the catalytic domain separated by a gate
from a channel that leads through the membrane-binding
domain to the exterior of the protein. Recent work indicates
that the two monomers of each COX enzyme are functionally
interdependentandthatbindingofasubstrateorinhibitoratone
active site alters the properties of the other active site (2). The
communication between subunits occurs through the dimer
interface (3).
COX-2 oxygenates a range of fatty acyl substrates includ-
ing fatty acids, esters, and amides. Arachidonic acid (AA) and
2-arachidonoylglycerol (2-AG) are the best acid and ester sub-
strates and display comparable kcat/Km’s for oxygenation (4).
Despite this similarity, we report here that COX-2 oxygenation
of 2-AG is dramatically more sensitive to inhibition by a series
of acidic NSAIDs than is oxygenation of AA. In fact, these
compounds, which have been considered relatively weak COX
inhibitors (i.e., ibuprofen and mefenamic acid), inhibit 2-AG
oxygenation at concentrations that are orders of magnitude
lower than the concentrations required for inhibition of AA
oxygenation.
The potency of individual inhibitors toward AA and 2-AG
oxygenationwasdeterminedininstantaneousinhibitionassaysin
which the substrate and inhibitor were incubated in an O2
monitor followed by addition of murine COX-2 (mCOX-2)
purified as previously described (5). Substrate oxygenation velo-
cities were measured at multiple concentrations of substrate
and inhibitor. A plot of V vs [S] for AA oxygenation at increas-
ing ibuprofen concentrations demonstrated increased Km
app’s
but comparable Vmax’s consistent with competitive inhibition
(Figure 1A). Similar results were obtained with mefenamic acid
(Supporting Information, Figure S1). The KI’s were calculated
from a secondary plot of the dependence of Km
app on inhibitor
concentration (Supporting Information, Figure S2). Ibuprofen
exhibited a KI of 80 ( 20 μM, whereas mefenamic acid exhibited
a KI of 10 ( 5 μM.
Oxygenation of 2-AG was completely inhibited by the lowest
concentrations of inhibitors used in the experiments with AA
(ibuprofen-25 μM, mefenamate-5 μM), so a much lower con-
centration range was evaluated. In contrast to the results with
AA, increasing concentrations of inhibitor did not increase the
Km
app but rather decreased Vmax (Figure 1B for ibuprofen and
SupportingInformation,FigureS1formefenamate).Thegeneral
appearance of the V vs [2-AG] plots at different inhibitor
concentrations was not consistent with competitive inhibition
but was suggestive of noncompetitive inhibition. Thus,the KI for
ibuprofen was calculated from a secondary plot of 1/Vmax
app vs
[ibuprofen] and found to be 1.2 μM (Supporting Information,
Figure S3).
The concentrations of mefenamic acid that inhibited 2-AG
oxygenation were in the range of the enzyme concentration so
aKIcouldnotbecalculatedfromtheinhibitordata.Fortunately,
mefenamic acid quenches the intrinsic protein fluorescence of
apoCOX-2 (without heme) so experiments were conducted using
fluorescence quenching to monitor inhibitor association (6). The
equilibrium constant for dissociation (Kd) could be measured
by titration of mCOX-2 with mefenamic acid, as previously
described for darbufelone (7). Fitting the corrected data to a
logarithmic plot of fluorescence vs inhibitor concentration
y i e l d e da nE C 50 value representing the apparent Kd of quenching
(SupportingInformation,FigureS4).ThecalculatedEC50 wasin
the range of the protein concentration so it is only an approxi-
mation of the Kd. Therefore, the experiment was repeated at
varyingenzymeconcentrations,andaplotofEC50versusenzyme
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concentration was constructed. The y-intercept of this plot
(equivalent to the EC50 at infinitely small enzyme concentration)
provided an estimate of the true Kd (4 nM).
These data suggest that ibuprofen and mefenamic acid inhibit
COX-2 oxygenation of AA and 2-AG by different mechanisms
and with different potencies. An interpretation of the experi-
mental findings can be made that is consistent with recent results
establishing that the two subunits of the homodimeric COX-2
protein are not identical once substrate or inhibitor is bound (2).
In the case of 2-AG oxygenation, binding of ibuprofen or
mefenamate at one subunit prevents productive binding of
2-AG at the other subunit.Therefore, a singlemoleculeof bound
inhibitor suffices to inhibit 2-AG oxygenation (Figure 2). The
KI for inhibition by ibuprofen and the Kd for binding of
mefenamate suggest high affinity binding at the first COX-2
subunit. The kinetics of ibuprofen and mefenamate inhibition of
2-AG oxygenation are typical of noncompetitive inhibition,
consistent with the hypothesis that binding of the inhibitor at
one subunit inhibits productive binding of 2-AG at the other
subunit. We cannot rule out the possibility that a separate, high
affinity allosteric binding site exists for these compounds outside
oftheactivesite,butitseemsunlikelygiven(a)thehighaffinityof
the inhibitors for the protein, (b) the existence of crystal
structures demonstrating the presence of arylcarboxylic acid
inhibitors in the active sites of both subunits, and (c) the
likelihood that the active site residue, Trp-387, is responsible
for the fluorescence quenched by mefenamic acid.
In contrast to the observations with 2-AG, inhibition of COX-2
oxygenation of AA by ibuprofen or mefenamate requires much
higher concentrations of inhibitor and displays kinetic behavior
typical of competitive inhibition. The most straightforward
interpretation of these results is that inhibition of AA oxygena-
tion requires inhibitor molecules to bind in both active sites
(Figure 2). Binding in the first active site is necessary but not
sufficient to inhibit AA oxygenation; inhibition is only observed
when the second molecule of inhibitor binds. Binding in the
first active site must decrease the affinity of the unoccupied
active site for the second molecule of inhibitor so that higher
concentrations are required and their binding is competitive
with that of AA.
Several arylcarboxylic acids or diarylheterocycles are slow,
tight-binding inhibitors of COX-2 (8). These compounds exhibit
low Kd’s for binding and potent inhibition but only after a
lengthy preincubation period. The indoleacetic acid derivative,
indomethacin, is a classic slow, tight-binding inhibitor of both
COX-2andCOX-1(9).InhibitionofAAoxygenationbyCOX-2
requiresapreincubationperiodofupto15min,anditsinhibition
potency increases dramatically during this time. Binding of a
single molecule of indomethacin to a COX homodimer is
sufficient to inhibit AA oxygenation (10). Following a 15 min
preincubation, indomethacin displayed an IC50 of 2 μMf o r
inhibition of AAoxygenationand 5.5μM for inhibition of 2-AG
oxygenation (Figure 3). Thus, a single indomethacin molecule
bound in one subunit is sufficient to inhibit the oxygenation of
eitherafattyacidorfattyacidestersubstrateintheothersubunit.
A major determinant of the slow, tight binding of indometha-
cin to COX-2 is insertion of the 20-methyl group on the indole
ring into a hydrophobic depression in the side of the COX-2
active site (11). Removal of the 20-methyl group generates a
molecule, 20-des-methylindomethacin, which exhibits rapid re-
versible inhibition of AA oxygenation with a much higher IC50.
Figure 3 demonstrates that removal of the 20-methyl group from
indomethacin increases the IC50 for inhibition of AA oxygena-
tion from 2 μM for indomethacin to ∼500 μMf o r2 0-des-
methylindomethacin. Incontrasttothe results withAA, removal
of the 20-methyl group from indomethacin has no effect on the
FIGURE 1: Inhibition of mCOX-2 oxygenation of AA and 2-AG by
ibuprofen. Ibuprofen and substrate were mixed in an oxygraph cell,
and the reaction was initiated by addition of COX-2. The initial
velocity of O2 uptake was determined from a tangent to the most
rapidly descending portion of the curve. (A) Ibuprofen at 0 μM( 9),
50 μM( O), 200 μM( 2), and 300 μM( b). (B) Instantaneous COX-2
inhibition of 2-AG oxidation by ibuprofen at 0 μM( 9), 0.5 μM( 1),
1.25 μM( (), and 2.5 μM( b).
FIGURE 3: Determination of IC50 values for the inhibition of
mCOX-2 oxygenation of AA and 2-AG by indomethacin and
20-des-methylindomethacin. mCOX-2 was preincubated with indo-
methacin (b)o r2 0-des-methylindomethacin (9) for 2 min before the
addition of 2-AG. For AA, maximal inhibition was achieved follow-
ing a 15 min preincubation with indomethacin (O)a n da2m i n
preinucation with 20-des-methylindomethacin (0). Inhibitor concen-
trations ranged from 250 nM to 500 μM. Following the addition of
50 μM substrate, rates of oxygen uptake were determined and
normalized to a DMSO control.
FIGURE 2: Model for differential inhibition 2-AG and AA oxygena-
tion by COX-2. The uninhibited mCOX-2 homodimer (blue) is able
to effectively metabolize both AA and 2-AG to form PGG2 and
PGG2-G. Binding of an inhibitor (yellow) to a single monomer
(green) precludes the productive binding of 2-AG in the partner
monomer (red) but still allows for AA oxygenation. Metabolism of
AA is inhibited only when an inhibitor occupies both active sites of
the COX dimer as shown on the far right.Rapid Report Biochemistry, Vol. 48, No. 31, 2009 7355
inhibition of 2-AG oxygenation; the IC50 for inhibition of 2-AG
oxygenation by 20-des-methylindomethacin is 6.8 μM, essentially
the same as the IC50 of indomethacin (Figure 3).
RomeandLandsfirstdemonstratedthatsomeCOXinhibitors
display rapid, reversible inhibition, whereas others exhibit slow,
tight-binding inhibition after the initial rapid, reversible interac-
tion with the enzyme (9). The rapid, reversible inhibitors are
relatively weak inhibitors of AA oxygenation, whereas the slow,
tight-binding inhibitors are more potent. The slow, tight-binders
exhibit very low dissociation rates so they are poorly reversible
even in the presence of saturating concentrations of AA. The
validity of the two-step mechanism of inhibition has been
demonstrated repeatedly and in some cases extended as exem-
plified bycertaindiarylheterocycles,which demonstratea second
time-dependent step responsible for COX-2 selective inhibi-
tion (12-14). Subsequent work has revealed that for several
slow, tight-binding inhibitors (e.g., indomethacin, flurbiprofen)
association of only a single molecule of inhibitor is sufficient to
inhibit the activity of both subunits, and this can be understood
by the recent discovery that the two subunits communicate
through the dimer interface (2).
The results of the present experiments demonstrate that both
reversible and time-dependent inhibitors can potently inhibit
oxygenation of the fatty acid ester substrate 2-AG and that some
of the reversible inhibitors (e.g., ibuprofen and mefenamate)
actually display much higher affinity for the enzyme than
originally thought as judged by their KI’s for inhibition and
Kd’s for binding. The Kd for ibuprofen and the KI for mefenamic
acid establish these compounds as high affinity ligands for first
subunit binding. The differential potency and mechanism of
inhibition of 2-AG oxygenation compared to AA oxygenation
displayed by ibuprofen and mefenamic acid adds a new dimen-
sion to our understanding of COX inhibition by this class of
compounds. They actually associate much more tightly with
COX-2 than previously appreciated and prevent the productive
binding of 2-AG but not AA. Their status as relatively weak,
rapidly reversible COX inhibitors derives from the fact that they
have to bind to both subunits of COX-2 (and presumably COX-1)
to inhibit productive binding of AA and that binding in the
second subunit is competitive with AA.
Our data suggest that binding of a single molecule of ibupro-
fen, mefenamic acid, indomethacin, or 20-des-methylindometha-
cin is sufficient to cause noncompetitive inhibition of 2-AG
oxygenation but only indomethacin inhibits AA oxygenation
under these conditions. These observations indicate that
although all of the inhibitors induce conformational changes in
thesecondsubunitfollowingbindinginthefirstsubunit,thereare
differences in the nature of the conformational changes induced
as judged by the differential effects on 2-AG and AA binding in
the second subunit. In addition, this differential sensitivity to
inhibitionrevealsdifferencesinthebindingof2-AGandAAthat
are not anticipated by the similarities in the kcat/Km for oxygena-
tion of the two substrates (4).
Inhibition of 2-AG oxygenation provides a powerful tool with
which to investigate the binding of NSAIDs to COX-2. It will be
interesting to examine a broader range of inhibitors than
described here for their ability to differentially inhibit the
oxygenation of 2-AG and AA and to compare the molecular
determinantsforthisdifferentialinhibition.Itisalsointriguingto
consider the possibility that the greater potency for inhibition of
2-AG oxygenation exhibited by certain NSAIDs against purified
protein has implications for understanding the pharmacological
properties of these compounds in vivo.
SUPPORTING INFORMATION AVAILABLE
Figures S1-S4. Thismaterial isavailablefreeof charge viathe
Internet at http://pubs.acs.org.
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